Caribou’s CAR T Exit: What it Means for 2027

Caribou Biosciences just pulled the plug on its allogeneic CAR T cell programs, and the decision has everyone in biotech talking about the money. While CAR T therapies are an incredible new weapon against some cancers, the price tag for clinical trials and manufacturing is astronomical. These costs create huge roadblocks, affecting not just whether these treatments reach patients but also what kinds of research get funded in other fields, including advancements in areas like skin health. So, what does Caribou’s big pivot really tell us about the future of cell therapy?

The Looming Financial Shadow Over CAR T Development

CAR T therapy has been a legitimate lifesaver for some patients with blood cancers since the first FDA approval in 2017, offering hope where other treatments have run out of road. But getting from a lab discovery to a widely available treatment is a brutal, expensive slog. Caribou Biosciences, a company known for its work with CRISPR gene editing in CAR T cells, just made the tough call to shut down its allogeneic CAR T programs, including the promising CB-010 for B cell non-Hodgkin lymphoma and CB-011 for multiple myeloma. This wasn’t a failure of the science. It was a business decision based on the cold, hard economics of drug development today.

The problem, as anyone in biotech will tell you, is the mind-boggling cost of pushing these therapies through late-stage clinical trials. A single allogeneic CAR T product can burn through more than $500 million from the lab to market approval, and a huge chunk of that cash gets spent in Phase 2 and 3. For Caribou, sticking with its CAR T pipeline meant needing to raise hundreds of millions more, which is getting tougher in this market. The Phase 3 trial for CB-010 alone was pegged at over $120 million, an amount that’s hard to justify without a guaranteed path to dominating the market and getting a quick return. Caribou’s not alone here. Many smaller biotech firms just can’t compete with the deep pockets of big pharma in this capital-hungry field.

What Went Wrong First: The Allogeneic Hurdle

The whole point of allogeneic (“off-the-shelf”) CAR T was that it was supposed to be the next big thing after patient-specific (autologous) treatments. The idea was great on paper: use healthy donor cells to create a universal CAR T product, mass-produce it, and have it ready to go. This would get rid of the long and complicated vein-to-vein time of autologous therapies, making CAR T more accessible and, hopefully, cheaper. But the science and regulations turned out to be much harder than people thought.

One of the biggest problems is preventing graft-versus-host disease (GvHD), where the donor T cells start attacking the patient’s own body. Gene editing tools like CRISPR-Cas9, which Caribou helped pioneer, tried to solve this by knocking out genes like the T cell receptor (TCR), but they haven’t been able to eliminate the GvHD risk completely. On top of that, getting these engineered allogeneic cells to stick around and work in the patient’s body without being immediately rejected by the immune system has been another major challenge. Some of the early attempts saw the donor cells cleared out way too fast, giving them very little time to do their job.

Then you have the manufacturing problems. Keeping quality, potency, and safety consistent across huge batches of these genetically tweaked cells is a ridiculously complex process. The regulatory path for these new kinds of therapies is still being drawn which adds more uncertainty and cost to the whole endeavor. Several companies ran into major delays and surprise expenses trying to figure it all out. For example, a few early-stage allogeneic programs got hit with clinical holds because of unexpected side effects or weak results, forcing them into expensive redesigns and longer trials. These setbacks are just part of doing science, but they added up to make the road for off-the-shelf CAR T look much longer and more expensive than first hoped.

Caribou’s Strategic Pivot: Doubling Down on In Vivo Gene Editing

Faced with these mounting costs, Caribou made a hard pivot. They’re stopping all ex vivo CAR T work and putting all their cash into their in vivo gene editing platform. They haven’t given up on gene editing. They’re just shifting their focus to a method they think is more sustainable and has broader potential. The company is now concentrating on therapies where the gene editing machinery is delivered directly into the patient’s body to modify cells in their natural environment. This completely bypasses the complicated and costly ex vivo manufacturing that CAR T requires, where you have to take cells out, ship them, edit them in a lab, and then put them back in.

The direct beneficiary is their lead in vivo program, CB-011, which goes after solid tumors. By shifting money and people over, Caribou plans to hit the accelerator on CB-011’s development. They’re now aiming to file an Investigational New Drug (IND) application by late 2026 and get into the clinic in early 2027, which is much faster than their old timeline. The thinking is that in vivo gene editing offers a simpler path that could cut down both the time and the money needed to get these treatments approved. For instance, making a viral vector for in vivo delivery, while not simple, is often easier to scale and has a lower per-dose cost than the personalized cell processing needed for every CAR T patient. It’s a calculated bet that in vivo gene editing has a much better economic model for delivering on the promise of CRISPR.

The Broader Implications for Medical Research and Skin Health

What Caribou did forces a tough question on the whole research world, even in areas like skin health: how do we fund these incredibly expensive but promising therapies? If a company with a good CAR T program can’t make the math work, it’s a bad sign for the entire biotech sector.

Gene editing has huge potential for skin health research, especially for genetic conditions like epidermolysis bullosa or severe psoriasis. But developing those therapies will get the same hard questions about cost and scalability. If in vivo gene editing proves to be a more efficient development model, it might actually speed up research for genetic dermatology treatments. For example, delivering CRISPR tools directly to skin cells to fix a bad gene could become a much more fundable project for investors than trying to do it with complex ex vivo cell work. How companies like Caribou fare with these simpler gene editing approaches will definitely affect investment appetite for gene therapies across the board, including for skin diseases.

Tackling solid tumors with CB-011 is also a big deal. CAR T has had its wins in liquid tumors, but solid tumors have a complex structure that makes them a much tougher nut to crack for cell therapies. If in vivo gene editing can make a dent in solid tumors, it opens up a massive new area for treatment. The lessons learned in developing and commercializing these platforms could lead to new ways of treating skin cancers or even improving skin regeneration at a genetic level. This whole situation is forcing a recalibration in the advanced therapy space. It doesn’t mean CAR T is finished. It just means its future likely belongs to companies with deep pockets, truly standout clinical data, or a genius way to slash manufacturing costs.

Measurable Results and Future Outlook

The immediate payoff for Caribou is that their cash now lasts into late 2027. By cutting the high-burn CAR T programs, the company has given itself a vital two-year window to push its in vivo pipeline forward without the constant pressure of raising more money in a difficult market. This financial stability makes Caribou a much more attractive bet for investors who were getting nervous about the endless capital demands of CAR T development.

Success now depends on getting CB-011 and other in vivo candidates into the clinic quickly and, in the end, getting good data. If Caribou can show its in vivo programs are safe and effective in people, especially in something as tough as solid tumors, it will validate their entire strategy. A win here would establish a new, more efficient model for gene therapy development and could pull a lot more investment into similar platforms that don’t have the manufacturing headaches of cell therapy.

Expect more consolidation in the CAR T space. Companies with strong data, solid manufacturing, and big-pharma backing will push ahead. Others might follow Caribou’s lead and pivot, or they’ll get bought out. The focus will shift to CAR T designs that solve today’s problems, like improving persistence, but always with a sharp eye on the price tag. For fields like psoriasis skin, the innovation in gene editing platforms could lead to a new wave of therapies, but their development will be dictated by the same economic realities that Caribou just ran into. Scientific brilliance is no longer enough. You need a business plan that actually works.

Caribou’s move from CAR T to in vivo gene editing is a perfect example of a hard truth in biotech, your science has to have a sustainable business model behind it. By focusing its investment on its in vivo platform and its lead candidate CB-011 for solid tumors, the company has found a clearer and potentially cheaper path to market. This realignment gives them a two-year runway and could put them at the forefront of a more economically viable way to do gene therapy, with effects that will be felt far beyond oncology and into future research for conditions affecting skin health.